% 0期刊文章% Elisa Canu % Federica Agosta %弗朗西斯卡imperiale %一个皮拉尔玛丽亚·费拉罗%一个朱塞佩·马格纳尼%吉安卡洛Comi %斯特凡诺披肩%马西莫菲利皮主持% T测量句子生产原发性进行性失语(P5.181) % D J神经病学2018% % P P5.181 % V 90% N 15补充% X目的:测试句回文构词法的能力测试(SAT)区分non-fluent (nfv)和logopenic变体(lv)原发性进行性失语(PPA),这是两个最困难的PPA形式区首页别于基于语音生产。背景:PPA的三个临床表现反映异构神经病理基质体内很难被认可。语法缺失的存在与tauopathy和高可能是非常有用的诊断过程。然而,语法能力可能很难评估临床当病人有言论影响生产。在这项研究中,我们提出了一个衡量坐句子在病人语音干扰生产。设计/方法:我们招募13 nfvPPA 9 lvPPA语义PPA (svPPA)患者和4。参与者接受了坐,包括规范和非规范的句子。性能的准确性和时间完成总sub-session物品记录。表现在语法理解测试也被调查。神经心理功能nfvPPA和lvPPA组之间的比较。四个svPPA并不包括在统计分析,只用于定性语法影响性能的例子。结果:PPA集团采取了类似的时间来完成所有的sub-sessions坐下。lvPPA相比,nfvPPA病人显示差精度标准和非规范的句子。 Likely due to initial comprehension deficits in lvPPA with longer disease duration, both groups of patients performed similarly in the syntax comprehension test. As expected, svPPA qualitatively performed better than the other groups in all investigated domains.Conclusions: The SAT is a powerful tool for distinguishing nfvPPA and lvPPA. Although some lvPPA had longer disease duration, the SAT was still able to detect the differences in the two variants. Future studies in larger samples should test the performance of these measures for a correct classification at the single subject level.Study Supported by:The study was supported by the Italian Ministry of Health (grant number GR-2010-2303035).Disclosure: Dr. Canu has nothing to disclose. Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EXCEMED— Excellence in Medical Education. Dr. imperiale has nothing to disclose. Dr. Ferraro has nothing to disclose. Dr. Magnani has nothing to disclose. Dr. Comi has nothing to disclose. Dr. Cappa has nothing to disclose. Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Novartis, Teva Pharmaceutical Industries. %U